# NG-348

Source: https://onco.cc/drugs/ng-348/  
OnCo record `ng-348` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NG-348 is an experimental cancer-killing virus from Akamis Bio, tested in a completed phase 1 study for advanced epithelial tumours.

## Summary

NG-348 is an oncolytic adenovirus (T-SIGn), given into a vein, carrying a transgene from Akamis Bio. A tumour-selective adenovirus that makes infected tumour cells display CD80 and an anti-CD3 antibody fragment on their surface, so that T cells engage them directly. The company says a phase 1 study of NG-348 alone in metastatic or advanced epithelial tumours was completed and presented at SITC 2026, and its pipeline lists metastatic colorectal cancer as the intended use. No ClinicalTrials.gov record was found under NG-348 or NG348. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: NG348
- Tags: pipeline
- Code: NG-348
- Modality: Oncolytic adenovirus (T-SIGn), given into a vein, carrying a transgene
- Mechanism: A tumour-selective adenovirus that makes infected tumour cells display CD80 and an anti-CD3 antibody fragment on their surface, so that T cells engage them directly.

## Sources

- Akamis Bio pipeline: https://www.akamisbio.com/science-pipeline/pipeline/
- Akamis Bio release on NG-348 phase 1 data at SITC 2026: https://www.akamisbio.com/news/akamis-bio-to-present-data-from-a-phase-1-study-of-ng-348-in-patients-with-advanced-epithelial-tumors-at-sitc-2026/

## Connected records

- targets: [CD3](https://onco.cc/targets/cd3/), [CD80 (B7-1)](https://onco.cc/targets/cd80/)
- companies: [Akamis Bio](https://onco.cc/companies/akamis-bio/)

---
JSON: https://onco.cc/api/v1/entities/ng-348.json